October 2013, Vol 4, No 8

Amsterdam, The Netherlands—The antibody-conjugate ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, prolonged progression-free survival (PFS) in advanced HER2-positive breast cancer in a heavily pretreated population, according to the final results of the phase 3 clinical trial TH3RESA.
Read Article

Amsterdam, The Netherlands—Although much progress has been made in cancer care over the past couple of decades, a report presented at the 2013 European Cancer Congress emphasizes that on a global scale, the impact is far from equitable.
Read Article

A team of researchers at Sanford-Burnham Medical Research Institute, led by Robert Wechsler-Reya, PhD, Professor at Sanford-Burnham’s National Cancer Institute (NCI)-Designated Cancer Center and Director of the Tumor Initiation and Maintenance Program, discovered that they can block the rapid growth of cancerous brain cells by using small-molecule inhibitors.
Read Article

Researchers have identified new molecular markers—microribonucleic acids (RNAs)—that, combined with their target genes, are believed to be able to identify which breast cancer will metastasize to the brain.
Read Article

The cost of cancer care has become a frequent topic of conversation in oncology conferences and publications, as well as among other stakeholders, including patients and payers. In a recent editorial published in the Journal of Clinical Oncology, David G. Pfister, MD, Chief, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, joined the discussion, acknowledging previous discussions related to the cost of cancer drugs and the notion that the status quo in drug pricing allows for arbitrary setting of a price for a drug that is not necessarily based on a demonstration of true value.
Read Article

In a recent guest blog on the Harvard Business Review website, Toby Cosgrove, MD, President and CEO of the Cleveland Clinic in Ohio, suggested that value-based care represents a life-saving “breakthrough,” not unlike penicillin or decoding the human genome, by focusing on lowering costs and improving quality of care and outcomes as its main goals.
Read Article

The US Food and Drug Administration (FDA) granted accelerated approval to pertuzumab (Perjeta; Genentech) as part of a treatment regimen for the neoadjuvant setting (ie, before surgery) for patients with HER2-positive early-stage breast cancer. This is the first time that the FDA approved a drug for the neoadjuvant treatment of patients with breast cancer.
Read Article

On September 10, 2013, the Institute of Medicine (IOM), part of the National Academy of Sciences, published a 315-page report, titled “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis”.
Read Article

Amsterdam, The Netherlands—For the first time, a therapy for non–small-cell lung cancer (NSCLC) has achieved responses in smokers better than in nonsmokers. The antibody MPDL3280A also achieved good responses in squamous and adenoma histologic types of NSCLC.
Read Article

Hollywood, FL—Oncology growth for the next couple of years will be driven by several strong trends, according to Doug Long, Vice President of Industry Relations, IMS Health, who described these trends at the 3rd Annual Conference of the Association for Value-Based Cancer Care.
Read Article

Page 3 of 4